14 completed, 2 terminated, 2 withdrawn, 1 enrolling by invitation. 20 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 14, Terminated 2, Withdrawn 2, Enrolling by invitation 1, Unknown 1 |
| Phase 1 | 2 | Enrolling by invitation 1, Terminated 1 |
Follow lonafarnib: new trials by email Literature Review of lonafarnib trials Research Report on lonafarnib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) Progerinin, Lonafarnib - Hutchinson-Gilford Progeria Syndrome | Phase 2 | Completed | PRG Science & Technology Co., Ltd. | 10 | 2025-01-13 | 2026-10-02 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 26 | 2018-08-01 | 2021-12-14 |
| Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria Everolimus and lonafarnib - Progeria | Phase 1 / Phase 2 | Enrolling by invitation | Boston Children's Hospital | 80 | 2015-12-01 | 2026-04-02 |
| Titrating-Dose of Lonafarnib in Combination With Ritonavir lonafarnib, Ritonavir - Chronic Delta Hepatitis | Phase 2 | Completed | EIT Pharma, Inc. | 15 | 2015-09-01 | 2026-09-25 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Lonafarnib, Ritonavir, Placebo - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 22 | 2015-07-29 | 2018-09-25 |
| Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) lonafarnib, ritonavir, Pegylated interferon-alfa-2a - Chronic Hepatitis D Infection | Phase 2 | Completed | EIT Pharma, Inc. | 55 | 2014-12-01 | 2026-09-25 |
| Lonafarnib With and Without Ritonavir in HDV (LOWR-1) lonafarnib, peginterferon alfa-2a, ritonavir - Chronic Hepatitis D Infection | Phase 2 | Completed | EIT Pharma, Inc. | 21 | 2014-11-01 | 2026-09-25 |
| Lonafarnib for Chronic Hepatitis D Lonafarnib, Placebo - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 14 | 2011-12-01 | 2016-08-31 |
| Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Lonafarnib, Zoledronic Acid, and Pravastatin - Progeria | Phase 2 | Unknown | Boston Children's Hospital | 85 | 2009-08-01 | 2023-02-27 |
| A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Lonafarnib, Zoledronic Acid, Pravastatin - Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Completed | Boston Children's Hospital | 5 | 2009-03-01 | 2019-06-13 |
| Lonafarnib in Metastatic Breast Cancer Lonafarnib - Metastatic Breast Cancer | Phase 2 | Terminated | George Sledge | 29 | 2008-10-01 | 2016-02-18 |
| A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) Docetaxel plus lonafarnib - Prostate Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | Merck Sharp & Dohme LLC | 5 | 2007-06-01 | 2015-02-05 |
| Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria Lonafarnib - Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Completed | Monica E. Kleinman | 29 | 2007-05-01 | 2019-06-25 |
| Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer Lonafarnib - Epithelial Ovarian Cancer | Phase 2 | Completed | AGO Study Group | 105 | 2006-01-01 | 2012-06-29 |
| Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) Lonafarnib, Placebo, anastrozole - Breast Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 110 | 2003-12-01 | 2015-04-15 |
| Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme Temozolomide and SCH66336 - Glioblastoma Multiforme | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2001-09-21 | 2018-10-29 |
| Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) SCH66336 - Myelogenous Leukemia, Chronic | Phase 2 | Completed | M.D. Anderson Cancer Center | 13 | 2001-04-30 | 2018-10-30 |
| SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract gemcitabine hydrochloride, lonafarnib - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 34 | 2000-06-01 | 2012-09-24 |
| SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer gemcitabine hydrochloride, lonafarnib, conventional surgery - Liver Cancer | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 1998-10-01 | 2020-07-31 | |
| A Study of Lonafarnib With or Without Ritonavir in Patients With HDV Lonafarnib, Ritonavir - Chronic Delta Hepatitis | Phase 2 | Withdrawn | Eiger BioPharmaceuticals | 2021-02-16 |
Progeria (5) · Breast Neoplasms (3) · Hepatitis D (3) · Hepatitis D, Chronic (2) · Liver Diseases (2) · Brain Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Fibrosis (1) · Glioblastoma (1) · Glioma (1) · Hepatitis (1) · Hepatitis, Chronic (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Boston Children's Hospital (3) · EIT Pharma, Inc. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · AGO Study Group (1) · Eiger BioPharmaceuticals (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · George Sledge (1) · Jonsson Comprehensive Cancer Center (1) · Monica E. Kleinman (1) · PRG Science & Technology Co., Ltd. (1)
United States (11) · Turkey (Türkiye) (2) · Germany (1) · Netherlands (1)
Cihan Yurdaydin, MD (2) · Mark W Kieran, MD, PhD (2) · Theo Heller, M.D. (2) · Brian Leland-Jones, M.D. (1) · Christopher Koh, M.D. (1) · Eduardo B Martins, MD, DPhil (1) · George Sledge, M.D. (1) · Godefridus Peters, PhD (1) · Heiner Wedemeyer, MD, PhD (1) · Jorge Cortes, MD (1) · Mark Kieran, MD, PhD (1) · Monica Kleinman, M.D. (1) · Rafael G. Amado, MD (1) · Ronald De Wit, MD, PhD (1)
PMID 24795390, PMID 27400896, PMID 30664876, PMID 36507973, PMID 36919608, PMID 15911238, PMID 22083160, PMID 22460337, PMID 22564713, PMID 22752073, PMID 23012407, PMID 23179651, PMID 23897869, PMID 24249802, PMID 26189433, PMID 34860418